Category: Partners

Transition extending life of mine production underway

• Gold equivalent production of 11,437 Gold Equivalent Ounces (“GEO”) at AISC of $1,779/oz during Q2 2025

• Adjusted EBITDA of $7.4 million for Q2 2025

• Full year guidance of 55,000-60,000 GEO maintained: Production weighted to H2 as higher-grade underground mining and heap leach volumes increase

• Repayment of ~US$18m debt and payables at the MDN operations year to date- ~US$10m in Q2 2025

• 20,000 meter resource expansion exploration program at MDN underway

• Significant investment and progress at both the Lagoa Salgada and Mont Sorcier projects

• Positive Metallurgical results at Lagoa Salgada to be incorporated into Optimized Feasibility Study to be delivered by year end

• Management to host conference call on Monday, 25^th of August, 11AM EDT

TORONTO, ON / ACCESS Newswire / August 21, 2025 / Cerrado Gold Inc. (TSXV:CERT)(OTCQX:CRDOF)(FRA:BAI0) (“Cerrado” or the “Company“) announces its operational and financial results for the second quarter (“Q2/25”) including its Minera Don Nicolas (“MDN“) gold mine in Santa Cruz Province, Argentina, its Lagoa Salgada Polymetallic Project in Portugal and its Mont Sorcier High Purity DRI Iron Project in Quebec. Financial results now include the consolidated financial position of Ascendant Resources Inc. (“Ascendant”) following the close of the acquisition effective May 16, 2025.

Production results for MDN were previously released on July 17, 2025. The Company’s financial results are reported and available on SEDAR+ (www.sedarplus.com) and the Company’s website (www.cerradogold.com).

Q2/25 MDN Operating Highlights:

• Q2/25 production of 11,437 GEO and AISC of $1,779/oz

  • Unit costs expected to continue to decline as production increases in H2/2025

• Q2/25 Adjusted EBITDA of $7.4 million

• Record heap leach production of 7,864 GEO during the Quarter

• Underground development at Paloma started with three access portals

• CIL plant receiving initial contribution from underground development; production expected to ramp up over H2/2025

Operational results for the second quarter saw gold production increase compared to Q1 2025, but were lower than Q2/24 during which period the high grade Calandrias Norte pit was being mined. This was anticipated given the depletion of high-grade material from Calandrias Norte, following which, MDN became primarily a heap leach only operation pending the ramp up of new high-grade material from underground. The heap leach operation reached another production record of 7,864 GEO for the quarter. The recently expanded crushing circuit is enabling higher volumes of ore to be placed on the pad, with further increases expected following the planned addition of an agglomerator and additional conveyors in Q3 2025. With higher gold prices, the CIL plant continued to process lower-grade stockpiles through Q2/25. Going forward, lower grade material will be blended with new high-grade material from underground mining feed beginning in Q3/25 which will increase mill grades, boost production and lower unit operating costs further.

Mark Brennan, CEO and Chairman commented, “The results from the second quarter demonstrate a robust operation transitioning to deliver increased production in the second half of the year and beyond. The expanded and improved crushing capacity at the heap leach is delivering greater production and when combined with new, higher-grade ore expected from underground operations, unit costs are expected to decline significantly in the second half of the year, enhancing our financial performance.”

He continued, “The strong cash flow generated from operations combined with our cash balance, has enabled us to pay down $10m in debt at MDN during the second quarter, while continuing to deploy capital for surface exploration and development of new resources underground. We are also seeing very positive advances at our Lagoa Salgada Polymetallic Project and at the High-grade Mont Sorcier DRI Iron Project in which we expect to unlock significant value that we see in these projects as the respective Feasibility Studies are completed.”

Operating Results for the Quarter

Operational results for Q2 2025 showed a modest increase in production over the previous quarter, driven by modestly higher production from the heap leach operations. The heap leach performance remained steady over the quarter. However, recovery rates were impacted by a larger amount of primary ore placed on pad during the quarter due to mine sequencing. This primary material has lower recovery rates and longer retention times as compared to oxide material. Heap leach production is expected to improve in H2/25 as more oxide ore is mined, the addition of an agglomerator to reduce fines is implemented, and the ongoing upgrades to the crushing circuit are completed. In addition, early in the quarter the crushing circuit was offline for approximately 15 days as upgrades were put in place to support higher throughput rates moving forward. Production from stockpiled material via the CIL plant declined somewhat due to lower grades, however, underground operations at Paloma are expected to begin to contribute meaningfully to production in H2 2025 and beyond as development rates increase and more ore becomes available.

The second phase of the expansion of the heap leach crushing circuit is now complete, which will increase feed stability in order to deliver steady ore volumes to the pad. While supporting higher production rates, additional crushing facilities are also expected to reduce the feed size to the pad and result in increased recoveries. The final updates to the crusher circuit, including final installation of the agglomerator and additional conveyors, are set to be completed in Q3/25.

As previously announced, MDN commenced underground mining in June, opening up three portals for underground mining beneath the Paloma pit. Ore production is expected to ramp up over H2 and is set to make a material contribution to production rates as the year progresses. While initial production expectations are relatively modest given the current known underground resource, underground access is expected to provide a platform for major exploration activities at a lower cost than drilling from surface. Underground exploration aims to materially expand resources at MDN, leveraging the underground development for a potential expansion in production and/or mine life.

On the exploration front, the Company commenced an approximate 20,000 metre drill program at MDN late in the quarter and is set to drill numerous targets in the coming months with the aim to potentially define new resources to provide mill feed to the CIL plant. Drilling commenced with a single DDH rig north of the Paloma pit, where several new veins have been intersected. Results are pending and further drilling will be required to confirm new resources.

In the near term, the focus at MDN remains to ramp up production rates at its heap leach operation to approximately 4,000-4,500 GEO per month, grow underground production from the Paloma area in H2, and ramp up a new targeted exploration program across our 330k Ha property to increase resources and mine life.

The Company has reduced its debt position by approximately $10M over the quarter at MDN and is well positioned to have a robust financial position by year end. Strong cashflow and reduced liabilities at MDN will support continued development and exploration at MDN, while pushing forward its strategic development programs at its projects in Quebec and Portugal.

Q1 Financial Performance

Table 1. Q1 2025 Operational and Financial Performance

The Company produced 11,437 gold equivalent ounces (“GEO”) during the three months ended June 30, 2025, as compared to 16,255 GEO for the three months ended June 30, 2024. In the period ended June 30, 2025, heap leach production was significantly higher compared to the prior year due to 27% higher recoveries and 438,530 additional tonnes placed on the pad. This was offset by a 10,262 ounce decrease in production from the CIL operation as the Company’s focus moved towards heap leach operations in 2025 and only processed low grade ore in Q2 2025.

The Company generated revenue of $29.6 million for the three months ended June 30, 2025, from the sale of 10,301 ounces of gold and 56,839 ounces of silver at an average realized price per gold ounce sold of $2,684. For the three months ended June 30, 2024, the Company generated revenue of $34.7 million from the sale of 15,484 ounces of gold 23,509 ounces of silver. Revenue is lower for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024, due primarily to lower gold ounces sold.

Cost of sales for the three months ended June 30, 2025, were $23.4 million as compared to $23.1 million for the three months ended June 30, 2024. The Company incurred $0.6 million higher production costs for the three months ended June 30, 2025 due to slightly higher costs of operational contractors and labour costs in 2025 as compared to 2024. Sales expenses were also slightly higher in the first quarter of 2025 by $0.6 million, offset by a $1.0 million decrease in depreciation expense.

Total cash costs (including royalties) sold was $1,770 per ounce in the three months ended June 30, 2025, as compared to $1,178 per ounce for the three months ended June 30, 2024, a $592 per ounce or 50% increase (refer to reconciliation of Non-IFRS performance metrics). The increase is a result of lower ounces sold in 2025 as compared to 2024.

Net income from continued and discontinued operations for the three months ended June 30, 2025, was $1.2 million as compared to a net income of $1.0 million for the three months ended June 30, 2024. The increase in net income is primarily a result of decrease in foreign exchange loss of $5.9 million and lower depreciation expense of $1.0 million offset by $5.2 million decrease in metal sales, an increase in loss on remeasurement of MDN stream obligation of $0.8 million and an increase in loss on remeasurement of Ascendant secured note and stream obligation of $1.1 million.

The Company incurred general and administrative expenses of $2.8 million for the three months ended June 30, 2025, as compared to $2.5 million of general and administrative expenses incurred during the three months ended June 30, 2024. The increase was primarily a result of an increase in salaries of $0.1 million, consulting fees of $0.1 million and marketing and promotion of $0.1 million offset by a decrease in stock-based compensation of $0.1 million, and office and other of $0.1 million for the three months ended June 30, 2025.

Other loss of $1.4 million during the three months ended June 30, 2025, includes finance expense of $1.4 million, loss on fair value remeasurement of MDN stream obligation of $1.0 million and loss on fair value remeasurement of Ascendant secured note and stream obligation of $1.1 million offset by finance income of $1.0 million and foreign exchange gain of $0.9 million.

Hedging Program

On April 26, 2025, the Company extended its limited hedging program with Ocean Partners UK Ltd. The hedge is constructed as a zero-cost collar with lower and upper boundaries of US$3,100 and US$3,250 per ounce respectively. The hedging volume is for 2,000 ounces per month for a period of 7 months beginning May 2025 and terminating on or about December 2025, subject to production volume. With the expanded hedging program, the Company is focused on ensuring more than sufficient cash flows to further enhance its balance sheet and support funding requirements for its various growth programs.

Outlook

Entering H2 2025 and beyond, Cerrado’s MDN Heap Leach operations are benefiting from the recent improvements to its crushing infrastructure to grow and improve production rates. Higher gold prices have enabled the CIL plant to remain operational by processing lower grade stockpiles, and it is now set to benefit from the introduction of higher-grade ore from underground operations, which is expected to improve overall profitability and free cash flows.

The Company has maintained its 2025 annual production guidance to 55,000 – 60,000 GEO. AISC costs are expected decline in the second half of 2025 as production ramps up to deliver AISC of between $1,500 – $1,700 per GEO.

The 20,000-meter exploration program has begun and is focused on growing the known resources at MDN beyond those outlined in the most recent Mineral Resource Estimate (“MRE”). The focus remains on defining high grade-near surface targets that can readily be brought into the mine plan. The Company has developed an underground and a regional program to better understand the potential of known anomalies on the significant land package Cerrado holds at MDN. Drilling is now underway.

During Q2 2025 the Company closed the acquisition of all of the outstanding common shares of Ascendant Resources Inc. not already owned by the Company and thereby obtaining an effective 80% interest in the Lagoa Salgada VMS project on the Iberian Pyrite Belt in Portugal. Accordingly, financial statements reflect the consolidation of Ascendant financial information for the first time, which includes liabilities assumed by the Company in connection with the acquisition.

At the Lagoa Salgada project, work continued across key workstreams with the goal of reaching a construction decision by Q1 2026. Ongoing metallurgical testing has already delivered positive improvements and is expected to be completed imminently. Management considers the previously reported improvements to Capex and Opex at Lagoa to be very encouraging, and they will be integrated into the optimization program for the OFS. Significant positive results using Dense Media Separation on the Stockworks zone has warranted further analysis on mine and plant design. The expected result is a reduction in processing costs from this domain, but requires further detailed work to be undertaken before it can be incorporated into the OFS. Parallel workstreams to complete the OFS are currently ongoing and it is expected that the completion of the OFS will occur by year end.

The Company is also advancing the approval in the Environment Impact Assessment (EIA), after successfully receiving Article 16 approval from the Portuguese regulators. The Company expects to submit its revised EIA in October.

At the Mont Sorcier high grade and high purity DRI iron project operated by Cerrado’s wholly owned subsidiary Voyager Metals Inc., work continued to advance the project with several workstreams related to permitting, social license and the initiation of the Feasibility Study which is targeted to be completed during Q1 2026. The high quality of the concentrate, grading over 67% iron, from the Mont Sorcier project is well positioned to support growing demand from the global Green Steel transition due to the reduced emissions generated by steel producers using high grade concentrates.

Conference Call Details

Cerrado Management will host a conference call on August 25, 2025, at 11:00 AM EDT to discuss the Q2 Financial and Operational results. The presentation for the call can be found on the investor page on Cerrado Gold’s website at cerradogold.com. Call details are as follows:

Pre-Registration for Conference Call

Participants can preregister for the conference by navigating to:

https://dpregister.com/sreg/10202340/ffc98dcb64

Participants will receive dial-in numbers to connect directly upon registration completion.

Those without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-833-752-3576

PARTICIPANT INTERNATIONAL DIAL IN: 1-647-846-8340

PARTICIPANT INTERNATIONAL DIAL IN: 1-647-846-8340

Review of Technical Information

The scientific and technical information in this press release has been reviewed and approved by Andrew Croal P.Eng, Chief Technical Officer for Cerrado Gold, who is a Qualified Person as defined in National Instrument 43-101.

About Cerrado

Cerrado Gold is a Toronto-based gold production, development, and exploration company. The Company is the 100% owner of the producing Minera Don Nicolás and Las Calandrias mine in Santa Cruz province, Argentina. In Portugal, the Company holds an 80% interest in the highly prospective Lagoa Salgada VMS project through its position in Redcorp – Empreendimentos Mineiros, Lda. In Canada, Cerrado Gold is developing its 100% owned Mont Sorcier Iron project located outside of Chibougamou, Quebec.

In Argentina, Cerrado is maximizing asset value at its Minera Don Nicolas operation through continued operational optimization and is growing production through its operations at the Las Calandrias heap leach project. An extensive campaign of exploration is ongoing to further unlock potential resources in our highly prospective land package in the heart of the Deseado Masiff.

In Portugal, Cerrado focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession. Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant exploration and development opportunity, already showing its mineable scale and cashflow generation potential.

In Canada, Cerrado holds a 100% interest in the Mont Sorcier Iron project, which has the potential to produce a premium iron concentrate over a long mine life at low operating costs and low capital intensity. Furthermore, its high grade and high purity product facilitates the migration of steel producers from blast furnaces to electric arc furnaces, contributing to the decarbonization of the industry and the achievement of sustainable development goals.

For more information about Cerrado please visit our website at: www.cerradogold.com.

Mark Brennan
CEO and Chairman

Mike McAllister
Vice President, Investor Relations
Tel: +1-647-805-5662
mmcallister@cerradogold.com

Disclaimer

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements contained in this press release include, without limitation, statements regarding the business and operations of Cerrado, anticipated continued improvements in operating results and working capital position, future production and grade estimates, future cashflows, expectations regarding the CIL plant processing lower grade stockpiles, the potential for improvement at MDN’s heap leach operation and higher grade ore being processed at MDN, expectations regarding improvements in operating costs at MDN including reduction in AISC, additional capacity being added at the heap leach operation, the potential of underground operation at MDN, the anticipated timing of completing the feasibility study at the Mont Sorcier project, the potential for a construction decision at Lagoa Salgada and the expected timing and likelihood of receiving approval of the environmental impact assessment at Lagoa Salgada. In making the forward- looking statements contained in this press release, Cerrado has made certain assumptions. Although Cerrado believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, Cerrado disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

SOURCE: Cerrado Gold Inc.

View the original press release on ACCESS Newswire

OSHAOutreachCourses.com Releases 2025 “State of Workplace Safety” Report Based on Survey of 500 Workers

HOUSTON, TX / ACCESS Newswire / August 21, 2025 / A new report released by OSHAOutreachCourses.com reveals troubling insights into how American workers perceive safety at their job sites. The 2025 State of Workplace Safety Survey is based on responses from 500 workers across construction, manufacturing, logistics, and retail sectors. It highlights both strengths and critical areas for improvement in workplace safety protocols.

The survey, conducted in the first half of 2025 through email and social media outreach, found that while some workers feel adequately protected, many continue to experience safety lapses that could lead to dangerous outcomes.

“These findings are a wake-up call. While safety equipment and basic procedures may be in place, true safety culture requires active listening, preparedness, and consistent training,” said Farhan Siraj, CEO of OSHA Outreach Courses. “There are some harrowing gaps in how safety protocols are implemented and how worker concerns are addressed.”

Key Findings from the 2025 Report:

• 10% of Workers Feel Very Unsafe at Work:
  Despite 22% of respondents saying they feel “very safe,” nearly 42% feel neutral, unsafe, or very unsafe. 10% workers specifically reported feeling unsafe at work.

• 18% of Workplaces Do Not Conduct Safety Drills:
  While 35% of workplaces conduct monthly safety drills, nearly one in five workers reported never participating in any drills.

• 9% Say Their Safety Concerns Are Ignored:
  Only 26% of workers said their safety concerns are always taken seriously by management. Alarmingly, 9% reported that their concerns are ignored altogether.

• 33% Do Not Receive Online Safety Training:
  Though 61% of workplaces offer online safety training, a third of workers reported they do not receive such training.

There are many positive findings of the survey as well such as 88% of workers reporting consistent access to personal protective equipment (PPE), and all respondents knew the location of emergency exits.

Workers Call for Action

When asked what improvements they would like to see, workers frequently cited better communication with management, more consistent training programs, and greater collaboration on safety planning. Several also emphasized the need for realistic disaster and emergency simulations.

A Call for Safer, More Prepared Workplaces

“This data shows that while we’ve made strides in some areas, there’s still work to be done,” explained Farhan.

The 2025 State of Workplace Safety Survey underscores the urgent need for stronger internal communication, routine drills, and widespread access to safety training to make sure that every worker feels safe and supported on the job.

About OSHA Outreach Courses

OSHAOutreachCourses.com is a leading provider of OSHA-authorized online safety training for workers and supervisors across the United States. It provides user-friendly e-learning solutions, to help organizations build safer, smarter, and more compliant workplaces.

Read More: https://www.oshaoutreachcourses.com/press/state-of-workplace-safety-report/

Contact:
Email: help@oshaoutreachcourses.com
Website: www.oshaoutreachcourses.com

SOURCE: OSHA Outreach Courses

View the original press release on ACCESS Newswire

LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver Trevena has joined as an investor, special advisor, and ambassador.

Trevena, a multi-talented actor, producer, investor, and entrepreneur, brings a powerful blend of star power, business acumen, and philanthropic passion to LKA. Known for his roles in The Plane, The Paradox Effect, and The Gorge, and recently named “Breakout Star” at the 2024 Rome Film Festival, Trevena’s career spans film, television, and hosting, with appearances at The Grammys, The American Music Awards, and The Hollywood Reporter.

Beyond Hollywood, Trevena is a serial entrepreneur and investor in purpose-driven brands like DOGPOUND, Vital Red Light, Allsaints, Juntos, Next Health, Artha, Happy Viking, and Cloud23. He co-founded Caliwater with Vanessa Hudgens, a cactus water brand that’s redefining functional beverages, which recently reached a $100 million valuation and welcomed Demi Lovato as a brand partner and investor.

Trevena’s deep commitment to health, food, and impact-driven ventures aligns perfectly with LKA’s mission: to provide an environment and curriculum where children and teens develop independence, confidence, and healthy habits, empowering them to change their lives and those around them.

“Little Kitchen Academy isn’t just teaching children to cook, they’re creating a healthier, more empowered generation,” said Oliver Trevena. “As someone who’s spent years investing in brands that inspire, improve lives, and ignite meaningful change, their commitment to helping children discover confidence through cooking is powerful and so necessary for our future generations; I’m honored to be a part of it.”

With Trevena joining the ranks of LKA’s influential circle of supporters, the Academy’s reach and impact are poised to grow even further. Alongside luminaries such as Celebrity Chef Cat Cora, NBA Icon Russell Westbrook, and Hollywood legend Supermensch Shep Gordon-each bringing their own expertise and passionate advocacy-Trevena is set to amplify LKA’s mission on a global scale. Their collaborative efforts will not only elevate LKA’s presence as the leader in Montessori-inspired culinary education but will also ensure that children from all over the world can benefit from learning essential skills, empowering them to change their lives from scratch and those around them.

“Oliver’s passion for wellness, education, and social impact resonated with us from the very first time we met at Little Kitchen Academy,” said Brian Curin, Co-Founder, CEO and CMO of Little Kitchen Academy. “Our initial conversation struck a profound chord with Oliver, as we discovered an authentic connection on every level-his values, vision, and voice not only support our mission, but also empower us to reach more families in meaningful ways.”

For more information, visit littlekitchenacademy.com or follow LKA on Facebook, Instagram, LinkedIn, and YouTube

About Little Kitchen Academy

Little Kitchen Academy is the premier Montessori-inspired cooking academy where every child and teen can develop independence, confidence, and healthy eating habits, empowering them to change their lives and those around them. It’s about more than cooking; it’s about making informed, healthy choices that contribute to a better society. With strategic partners including, BIRKENSTOCK, Celebrity Chef Cat Cora, ChefWorks, ChopValue, Click & Grow, Emeco, IKEA, Küssi, PRISE Inc., NBA Icon Russell Westbrook, Scrub Daddy, Supermensch Shep Gordon, and Welcome Industries, and charitable partnerships including, the Changing Lives From Scratch Fund, The Russell Westbrook Why Not? Foundation, Crisis Text Line, Kids Help Phone, and One Tree Planted, Little Kitchen Academy is dedicated to serving a brighter future. Little Kitchen Academy’s flagship locations are in Vancouver BC, Denver, and Los Angeles.

For a taste of Little Kitchen Academy, visit littlekitchenacademy.com or join its communities on Facebook, Instagram, LinkedIn, and YouTube

FOR MORE INFORMATION

Little Kitchen Academy
Curin@LittleKitchenAcademy.com
1.604.928.0629

SOURCE: Little Kitchen Academy

View the original press release on ACCESS Newswire

SOUTHLAKE, TX and SOUTH BEND, IN / ACCESS Newswire / August 21, 2025 / Allied OMS, the nation’s leading doctor-owned and doctor-led management services organization (MSO) for oral and maxillofacial surgeons, today announced its official entry into Indiana through a new partnership with Oral Surgery Michiana.

Led by Drs. William Hull and Edward Collins, Oral Surgery Michiana operates two state-of-the-art surgical centers in South Bend and Elkhart, Indiana. The practice provides the full scope of oral and maxillofacial procedures and is known for its precision, advanced technology, and deeply patient-centered approach. With decades of experience and a commitment to both comfort and clinical excellence, the team has become a trusted provider across northern Indiana and southern Michigan.

“Drs. Hull and Collins are deeply aligned with our mission – passionate, caring surgeons who demonstrate high integrity and dedication to innovation,” said Dan Hosler, CEO of Allied OMS. “They embody the kind of doctor-entrepreneurs we built this platform for, and we’re thrilled to partner with them as we deepen our existing presence in the Great Lakes region.”

The partnership reflects what the Oral Surgery Michiana team was seeking: meaningful growth support without compromising the identity they’ve built.

“We weren’t just looking for a buyer – we were looking for a partner who would help us elevate our brand and infrastructure while staying true to who we are,” said Dr. Hull.

“Allied OMS’s doctor-centric model challenges us to be better, not different,” added Dr. Collins. “Their transparency and collaborative spirit throughout the process made it clear this was the right fit.”

“Throughout our partnership diligence process, I got to personally know Drs. Hull and Collins. I saw that not only are they outstanding surgeons, but they are also compassionate, servant-led individuals,” said Dr. David Kostohryz, Co-Founder of Allied OMS. “At Allied OMS, culture is paramount to our success, and I know that they are going to be a great addition to our family.”

About Allied OMS
Allied OMS is a doctor-owned, doctor-led, and doctor-governed MSO that partners with oral and maxillofacial surgery practices across the U.S. Combining the autonomy of private practice with the scale and sophistication of institutional support, Allied OMS empowers surgeons to lead the future of their specialty. The company currently supports surgeons in 50+ locations and maintains doctor leadership across all major committees and its Board of Directors. Learn more at www.alliedoms.com.

About Oral Surgery Michiana
Located in South Bend and Elkhart, Indiana, Oral Surgery Michiana is a trusted provider of full-scope oral and maxillofacial surgical care, serving patients across northern Indiana and southern Michigan. Led by board-certified surgeons Dr. William Hull and Dr. Edward Collins, the practice offers expertise in dental implants, wisdom teeth removal, bone grafting, corrective jaw surgery, and more – all delivered in a state-of-the-art surgical environment. Known for its use of advanced imaging and anesthesia techniques, the practice is committed to safety, comfort, and exceptional outcomes. With a longstanding reputation for clinical excellence and compassionate care, Oral Surgery Michiana is deeply rooted in the community it serves. Learn more at https://www.oralsurgerymichiana.com/.

##

Media Contact

Sara Tumen Weinberg
Chief Marketing Officer
Allied OMS
sweinberg@alliedoms.com

SOURCE: Allied OMS

View the original press release on ACCESS Newswire

New customer additions key driver of 16.2% product revenue growth in Q1 FY26

SALT LAKE CITY, UTAH / ACCESS Newswire / August 21, 2025 / FatPipe, Inc. (NASDAQ:FATN) (“FatPipe” or the “Company”), a pioneer in enterprise-class, application-aware, secure Software-Defined Wide Area Network (“SD-WAN”) solutions that provide the highest levels of reliability, security, and optimization for Wide Area Networks (WANs), today announced the addition of 174 new customers in the first quarter of fiscal year 2026. This surge in adoption contributed to a 16.2% year-over-year increase in product revenue compared to the same quarter of the prior fiscal year.

“The addition of 174 new customers in Q1 highlights the accelerating demand for FatPipe’s software-defined networking solutions,” said Dr. Ragula Bhaskar, CEO of FatPipe. “Customer growth is the foundation of our subscription-based model, and this momentum gives us confidence in our ability to drive sustainable, recurring revenue growth as we continue expanding in key markets globally.”

FatPipe’s momentum builds on its differentiated platform, which integrates Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), Cybersecurity, and Network Monitoring Services (NMS) into a unified solution. With patented multi-path routing, sub-second failover, single-stack security, and deep observability, FatPipe empowers enterprises to simplify network management, secure distributed operations, and ensure business continuity.

The company continues to serve a diverse base of more than 2,700 customers across sectors including government, healthcare, financial services, education, and retail, with growing international expansion in Southeast Asia and Mexico.

About FatPipe, Inc.

FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe products are sold by 200+ resellers worldwide. For more information, visit www.fatpipe.com. Follow us on X @FatPipe_Inc.

Forward-Looking Statements

Certain statements contained in this press release, including statements relating to the Company’s expectations regarding the completion, timing and size of its proposed public offering and listing may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on management’s current expectations and are inherently subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the offering and other risks described in FatPipe’s registration statement on Form S-1, as it may be amended from time to time. Except as required by law, FatPipe expressly disclaims a duty to provide updates to forward-looking statements, whether as a result of new information, future events or other occurrences.

Company Contact Info

Vikrant Ragula
Director of Investor Relations
801-683-5656 x 1140
Investor.ir@fatpipeinc.com

Investor Contact

Dave Gentry, CEO
RedChip Companies, Inc.
1.800.RED.CHIP (733-2447)
FATN@redchip.com

SOURCE: FatPipe Networks

View the original press release on ACCESS Newswire

Canalevia^® (crofelemer delayed-release tablets), under the name Canalevia^®-CA1, is conditionally approved by the FDA for treatment of CID in dogs

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Enrollment has reached approximately 25% in Jaguar’s ongoing field study of Canalevia-CA1 in dogs

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company’s goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri.

“I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs. Forging a partnership to support these goals is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for Jaguar this year.”

“Our goal is to be as comprehensive as possible in the search for the best partner for Canalevia – and with this goal in mind we look forward to participating in the 2025 Animal Health Summit. Our team is available for partnership discussions at the event,” said David Sesin, PhD, Jaguar’s Chief Manufacturing Officer.

A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022. “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs – both in the U.S. and the EU,” said Conte. “We estimate that U.S. veterinarians see approximately four million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally.”

As announced, enrollment has begun in Jaguar’s ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. With multiple veterinary oncology clinics signed on to take part in this study, enrollment has reached 25%, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation. The objective of this ongoing, prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs – the fourth and final technical section required to support potential full FDA approval of the drug for dogs with CID. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected for the control group.

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

“In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea,” Conte said. “While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia resolved their diarrhea within 24 hours of the first administration of the drug, with the data demonstrating statistical and clinical relevance compared to placebo-treated dogs.”

Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that company personnel will attend the 2025 Animal Health Summit, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea, Jaguar’s expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea, Jaguar’s expectation that, if the dossier is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs to the EMA, and Jaguar’s expectation that, if the application is approved by the EMA, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Source: Jaguar Health, Inc.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

ISTANBUL, TURKEY / ACCESS Newswire / August 21, 2025 / Established in Turkey, Esteworld now offers face-to-face consultations in London and continues its operations in its state-of-the-art hospitals in Istanbul. This combines clinical quality with the value that has made Turkey a global destination. Post-procedure care is provided in the country where the procedure was performed.

August 20, 2025

Esteworld announced the launch of a new office in London, marking the next step in the brand’s international growth. Having built its reputation by delivering hair transplant in Turkey services, Esteworld is expanding access for UK and European patients who want local guidance before and after surgery, with the procedure itself performed by experienced teams in Istanbul.

“Patients told us they want two things: the clinical excellence and value associated with Turkey, and the convenience of a local touchpoint,” said an Esteworld spokesperson. “Our London office brings those together. People can receive assessments, treatment planning, and follow-ups close to home, while their surgical journey remains anchored in our established Turkish hospitals.”

A seamless UK-Turkey care pathway

The London location is designed for consultations (not surgical procedures) so patients can meet a medical consultant, discuss candidacy, choose the most suitable hair transplant method, and understand the expected timeline before traveling. This model makes the experience more accessible for patients who prefer face-to-face guidance without sacrificing the standards and efficiencies that Turkey offers. A great opportunity for those who cannot have a hair transplant in London.

In Istanbul, Esteworld performs procedures such as FUE (Follicular Unit Extraction), Sapphire FUE, DHI (Direct Hair Implantation), and unshaven approaches for qualifying candidates. Technique recommendations are individualized, taking into account donor density, hair caliber, curl pattern, hairline design goals, and long-term planning to maintain a natural look as hair loss progresses.

About Esteworld

Established in 1994, Esteworld is an international healthcare group specializing in hair transplantation, plastic surgery, medical aesthetics, and dental aesthetics. With a network spanning 35+ countries, Esteworld delivers end-to-end patient pathways through coordinated local offices and advanced hospital facilities.

Esteworld’s hair restoration portfolio includes FUE, Sapphire FUE, DHI, and suitable unshaven approaches, supported by standardized clinical protocols, donor management strategies, and natural hairline design principles. Multilingual patient coordination, transparent pricing structures, and comprehensive post-operative follow-up are integral to the group’s service model.

Combining high surgical experience with evidence-based practice and rigorous safety standards, Esteworld focuses on outcomes that look natural and remain sustainable over time. The group’s integrated approach aligns medical necessity with aesthetic goals, providing patients a reliable, seamless, and internationally accessible care experience.

Why Turkey remains a leader in hair transplantation

Turkey’s prominence in hair restoration stems from high surgical volumes, specialized teams, and a service model that streamlines logistics for international patients. Many clinics (Esteworld included also) organize airport transfers, translation assistance, and post-operative kits to reduce friction during a short medical stay. The combination of experience, coordinated care, and competitive pricing has drawn patients from around the world.

About hair transplant prices in Turkey

While pricing always depends on the clinic, technique, surgeon seniority, and graft count, Turkey is widely recognized for cost-effective options compared with Western Europe and North America. Patients commonly encounter two pricing structures:

• All-inclusive packages: Frequently designed to cover consultation, the operation, routine medications, and ground transfers, with optional hotel add-ons. For many patients, total package prices often fall in a broad mid-four-figure range (in USD), with variability based on technique and the overall service bundle.

• Per-graft pricing: Some plans are quoted by graft. Typical ranges are often discussed in pre-assessment and can vary substantially depending on the complexity of the case and the chosen method (for example, FUE vs. DHI).

Because individual needs differ (some require 2,000 grafts, others 4,000 or more) final costs are best determined after a professional evaluation that considers donor capacity and long-term hair-loss patterns. Esteworld emphasizes transparent quoting so patients understand exactly what is included before traveling.

What patients can expect with Esteworld

Consultation & candidacy: At the London office, patients receive a structured assessment that reviews medical history, scalp condition, and donor area. The consultant discusses realistic outcomes, hairline philosophy, and potential graft counts, and sets expectations around the growth timeline.

Technique selection: FUE and DHI are the most frequently recommended techniques. FUE involves extracting follicular units individually and implanting them into micro-channels; Sapphire FUE uses sapphire-tipped tools for channel creation; DHI places grafts with pen-like instruments that allow precise angle and direction. The goal is to harmonize density, direction, and hairline shape with each patient’s unique features.

Surgery in Istanbul: Procedures are performed by dedicated teams in Esteworld’s Turkish hospitals, where standardized protocols govern anesthesia, sterile technique, graft handling, and recipient site creation. High case volumes help refine micro-surgical skills and consistency, supporting natural, age-appropriate results.

Safety, ethics, and realistic expectations

Hair transplantation is a medical procedure, not a commodity. Esteworld advocates for evidence-based practice and thorough informed consent. Not every patient is an ideal candidate. Donor limitations, diffuse thinning, scarring alopecia, or certain medical conditions may call for conservative plans or a staged approach. Adjunct therapies (including topical agents, oral medications when appropriate, low-level laser therapy, and PRP) may be discussed as part of a personalized long-term strategy.

A natural outcome depends on more than graft numbers. Key variables include the hairline’s anatomic placement, graft angulation, distribution in zones of visual priority, and respect for future hair-loss progression. Esteworld’s planning process prioritizes long-term aesthetics to avoid an unnaturally dense front with inadequate reserves for later.

The patient journey, step by step

1. Initial inquiry: Patients share photos and goals. A preliminary indication of candidacy and estimated plan is provided.

2. London consultation: A detailed assessment confirms technique options, estimated graft range, downtime, and budget structure (package vs. per-graft).

3. Preparation: Pre-op instructions cover medication adjustments, smoking and alcohol guidance, and scalp conditioning to optimize graft survival.

4. Travel to Istanbul: Coordinated transfers and scheduling streamline arrival. A final design session refines hairline, density, and coverage areas.

5. Procedure day: Extraction and implantation proceed according to plan, with attention to gentle handling and hydration of grafts throughout.

6. Immediate post-op: Patients receive a written care plan, washing tutorial, and protective measures for the first 10-14 days.

Value without compromise

By originating in Turkey and later opening a London office, Esteworld aims to combine the best of both worlds: the experience and efficiencies that come from a leading hair transplant Turkey ecosystem, and the reassurance of local, ongoing support. For many, this hybrid model shortens decision time, clarifies expectations, and maintains continuity from first conversation to final results.

“Patients deserve clarity,” the Esteworld spokesperson added. “Our approach is to explain the medical reasoning, set goals that make sense for the long term, and deliver attentive aftercare. Opening in London lets us do even more of that, face-to-face.”

Media Details :

Name: Burak Tuncer
E-mail: info@esteworldturkey.com
Phone number: +90 216 474 54 54
Web: https://www.esteworldturkey.com/

SOURCE: Burak Tuncer

View the original press release on ACCESS Newswire